Irvine Scientific Introduces DMSO-Free, Chemically-Defined Cryopreservation Solution for Mesenchymal Stem Cells

SANTA ANA, California – Nov 18, 2014 – Irvine Scientific, a world leader in the innovation and manufacture of cell culture media, announced today the addition of PRIME-XV® FreezIS DMSO-Free, a chemically-defined cryopreservation solution for human mesenchymal stem/stromal cells (MSCs) that is free of dimethyl sulfoxide (DMSO) and animal-derived components.

Amid growing concerns that DMSO may compromise the potency of MSCs, offering an effective DMSOfree cryoprotectant is an important addition to PRIME-XV product line. Researchers can now characterize cells in DMSO-free environments during basic and translational research, which may add valuable insight downstream and facilitate scale-up. PRIME-XV FreezIS DMSO-Free maintains the potency of MSCs throughout cryopreservation while sustaining comparable cell viability as solutions containing 10% DMSO.

“Providing an effective, DMSO-free cryopreservation solution can facilitate scale up by enabling researchers to develop reproducible and robust, clinical-friendly protocols in the early stages of translational research.” says Dr. Jessie Ni, Chief Scientific Officer of Irvine Scientific. “We are committed to leading the development of products utilizing the most current research and understanding of stem cell biology.”

For applications where the effects of DMSO are not as critical, Irvine Scientific also offers PRIME-XV FreezIS, a 10% DMSO-containing, protein-free, chemically-defined cryopreservation solution for a variety of cell types. Both cryopreservation solutions join the PRIME-XV line of cell therapy products, which are designed to offer the highest quality and performance for the culture of human stem cells and primary cells.

These products are manufactured under cGMP conditions for added consistency. View all the products at www.irvinesci.com/cell-therapy.

About Irvine Scientific

Irvine Scientific, a member of JX Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 40 years, Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

Download Press Release (PDF)